JP2023517243A5 - - Google Patents
Info
- Publication number
- JP2023517243A5 JP2023517243A5 JP2022554833A JP2022554833A JP2023517243A5 JP 2023517243 A5 JP2023517243 A5 JP 2023517243A5 JP 2022554833 A JP2022554833 A JP 2022554833A JP 2022554833 A JP2022554833 A JP 2022554833A JP 2023517243 A5 JP2023517243 A5 JP 2023517243A5
- Authority
- JP
- Japan
- Prior art keywords
- bcma
- subject
- nilogacestat
- dihydrobromide
- cell maturation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025139609A JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989372P | 2020-03-13 | 2020-03-13 | |
| US62/989,372 | 2020-03-13 | ||
| PCT/US2021/022177 WO2021183934A1 (en) | 2020-03-13 | 2021-03-12 | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139609A Division JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517243A JP2023517243A (ja) | 2023-04-24 |
| JP2023517243A5 true JP2023517243A5 (enExample) | 2024-03-21 |
| JP7781764B2 JP7781764B2 (ja) | 2025-12-08 |
Family
ID=75396879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554833A Active JP7781764B2 (ja) | 2020-03-13 | 2021-03-12 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
| JP2025139609A Pending JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139609A Pending JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230121547A1 (enExample) |
| EP (1) | EP4132515B1 (enExample) |
| JP (2) | JP7781764B2 (enExample) |
| KR (1) | KR20230009873A (enExample) |
| CN (2) | CN115916188A (enExample) |
| AR (1) | AR121566A1 (enExample) |
| AU (1) | AU2021236340A1 (enExample) |
| BR (1) | BR112022018251A2 (enExample) |
| CA (1) | CA3171267A1 (enExample) |
| CL (1) | CL2022002479A1 (enExample) |
| CO (1) | CO2022014388A2 (enExample) |
| IL (1) | IL296075A (enExample) |
| MX (1) | MX2022011258A (enExample) |
| PE (1) | PE20230614A1 (enExample) |
| TW (1) | TW202200132A (enExample) |
| WO (1) | WO2021183934A1 (enExample) |
| ZA (1) | ZA202209989B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024002590A (es) | 2021-09-01 | 2024-03-22 | Springworks Therapeutics Inc | Sintesis de nirogacestat. |
| WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| CN118338900A (zh) * | 2021-11-05 | 2024-07-12 | 斯普林渥克斯治疗有限公司 | 含尼罗加司他的组合物和治疗 |
| MX2024005453A (es) * | 2021-11-05 | 2024-07-22 | Springworks Therapeutics Inc | Composiciones y tratamientos con nirogacestat. |
| EP4436958A1 (en) * | 2021-11-23 | 2024-10-02 | Teva Pharmaceuticals International GmbH | Solid state forms of nirogacestat salts |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| IL316750A (en) | 2022-05-20 | 2025-01-01 | Springworks Therapeutics Inc | Treatments with Nirogesstat |
| US12667555B2 (en) | 2022-05-20 | 2026-06-30 | Springworks Therapeutics, Inc. | Treatment of ovarian cancer with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| JP2026508907A (ja) * | 2023-03-09 | 2026-03-13 | ▲蘇▼州科睿思制▲葯▼有限公司 | ニロガセスタット二臭化水素酸塩の結晶形、及びその調製方法並びに用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120065A1 (en) * | 2014-02-05 | 2015-08-13 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides |
| EP3324965A4 (en) * | 2015-07-24 | 2019-07-03 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| IL268349B2 (en) * | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| CN110622566B (zh) | 2017-05-05 | 2021-04-20 | 华为技术有限公司 | 一种辅助数据传输方法、设备及系统 |
| AU2018359907A1 (en) * | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| US11970542B2 (en) * | 2017-11-08 | 2024-04-30 | Fred Hutchinson Cancer Center | Bispecific antibodies specific for treating hematological malignancies |
| WO2019143818A1 (en) * | 2018-01-17 | 2019-07-25 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| BR112020023975A2 (pt) * | 2018-05-24 | 2021-02-23 | Ayala Pharmaceuticals Inc. | composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas |
| PE20210320A1 (es) * | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| MX2021012407A (es) * | 2019-04-10 | 2021-11-12 | Glaxosmithkline Ip Dev Ltd | Terapia de combinacion con un anticuerpo anti bcma y un inhibidor de gamma secretasa. |
| KR102772889B1 (ko) | 2019-08-09 | 2025-02-26 | 화이자 인코포레이티드 | (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의 고체 상태 형태 및 이의 용도 |
-
2021
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 JP JP2022554833A patent/JP7781764B2/ja active Active
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en not_active Ceased
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 CN CN202610227254.XA patent/CN122272572A/zh active Pending
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 EP EP21716907.7A patent/EP4132515B1/en active Active
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Pending
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
-
2022
- 2022-09-07 ZA ZA2022/09989A patent/ZA202209989B/en unknown
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
-
2025
- 2025-08-25 JP JP2025139609A patent/JP2025168430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Czuczman et al. | Rituximab in combination with CHOP or fludarabine in low-grade lymphoma | |
| Boye et al. | An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab | |
| DK2055313T3 (en) | Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody | |
| US9458241B2 (en) | Antibody induced cell membrane wounding | |
| US11220548B2 (en) | Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody | |
| US20050112130A1 (en) | Enhanced B cell cytotoxicity of CDIM binding antibody | |
| Sacchi et al. | Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab | |
| EA004107B1 (ru) | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2008530142A5 (enExample) | ||
| US20180228893A1 (en) | Combinations and uses thereof | |
| Lugtenburg et al. | First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBodyŪ-CD3ŨCD20) in B-Cell Non-Hodgkin Lymphomas | |
| JP2022532519A5 (enExample) | ||
| WO2025061140A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| Anastasia et al. | Novel drugs in follicular lymphoma | |
| Arcaini et al. | Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma | |
| Jäeger et al. | Rituximab (anti‐CD20 monoclonal antibody) as consolidation of first‐line CHOP chemotherapy in patients with follicular lymphoma: a phase II study | |
| Kawano et al. | The impact of a humanized CCR4 antibody (Mogamulizumab) on patients with aggressive-type adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation | |
| WO2024183818A1 (zh) | 抗cd20抗体药物偶联物在制备治疗非霍奇金淋巴瘤的药物中的用途 | |
| Candelaria | Advances in the diagnosis and control of lymphomas | |
| Longo | Biologic agents and approaches in the management of patients with lymphoma: a critical appraisal | |
| AU2020339737B2 (en) | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells | |
| JP2019524780A (ja) | プロテアソーム阻害剤及び抗ｃｄ３０抗体の組み合わせ | |
| Hagemeister | Mantle cell lymphoma: non-myeloablative versus dose-intensive therapy | |
| Qu et al. | ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R‐CHOP‐LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON‐GCB DLBCL. |